WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that the company, in partnership with Advantage Healthcare , will explore Quell ® retail expansion plans with executives from key national and regional drug chains and mass merchandisers at the NCADS Total Store
NeuroMetrix to Preview New Product Targeted at Diabetes Market at the American Association of Clinical Endocrinologists Annual Meeting WALTHAM, Mass., Apr 13, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it will preview its newest product - NC-stat ® | DPNCheck
BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell will be one of 30 companies to present their latest innovations at CES Unveiled New York on November 10 . CES Unveiled is produced by the Consumer Electronics Association to provide a sneak peek at the year's most
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) will unveil and demonstrate Quell, a novel wearable pain relief device at the 2015 International Consumer Electronics show (CES) January 6-9 in Las Vegas . Attendees will get their first glimpse of Quell at Booth # 73311 in the
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) and the Scripps Translational Science Institute (STSI) today announced a clinical study of Quell ® wearable pain relief technology in patients with cancer related pain. According to the National Cancer Institute , about 15 million
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) today announced a clinical study of Quell ® Wearable Pain Relief Technology™ in patients with chronic low back pain at the Brigham and Women's Hospital Pain Management Center.
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported that it anticipates commercial shipments of the Quell wearable pain relief device will begin in June 2015 . The Company also announced that it has officially started accepting pre-orders for Quell directly on its website
WOBURN, Mass. , June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain. This effort includes direct-to-consumer digital marketing as well as informing physicians and other health care providers
